DAAN Biotherapeutics and GC Cell Sign Exclusive Technology Transfer Agreement for Tumor Antigen-Specific Antibody Sequence to Advance CAR-T and CAR-NK Cell Therapies
SEOUL, South Korea, April 21, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-Cell receptor (TCR)-based therapies, has signed an exclusive licensing agreement with GC Cell, a gene and cell...
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy
YONGIN, South Korea, March 13, 2025 /PRNewswire/ -- GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5 CAR‑NK cell therapy. This...
GC Cell Symposium with Bifarma Expands Global Impact and Reach for Immuncell-LC
YONGIN, South Korea, Jan. 23, 2025 /PRNewswire/ -- GC Cell, a leading cell and gene therapy company, announced the successful completion of its first thought leadership symposium in Jakarta, Indonesia. The event was organized in collaboration with...